Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).
UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Applications for UMEC/VI are also planned in the European Union and in other countries next year.
FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.
Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.
RD
-
Inflation holds steady at 3.8% ahead of BoE meetingThe rate of inflation did not rise in August, but the Bank of England is still expected to keep interest rates on hold tomorrow
-
Thousands of savers with £250k pensions take cash over tax-free money and IHT fearsWith a record £70 billion withdrawn from pensions in the year to March, experts are concerned savers are making knee-jerk decisions without advice that could affect their long term wealth
